These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

462 related items for PubMed ID: 30450847

  • 1. Cancer Metabolism as a Mechanism of Treatment Resistance and Potential Therapeutic Target in Hepatocellular Carcinoma.
    Lee M, Ko H, Yun M.
    Yonsei Med J; 2018 Dec; 59(10):1143-1149. PubMed ID: 30450847
    [Abstract] [Full Text] [Related]

  • 2. 18F-Fluorodeoxyglucose uptake on positron emission tomography/computed tomography is associated with metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma.
    Lee M, Jeon JY, Neugent ML, Kim JW, Yun M.
    Clin Exp Metastasis; 2017 Apr; 34(3-4):251-260. PubMed ID: 28429188
    [Abstract] [Full Text] [Related]

  • 3. Role of FDG-PET in the evaluation and staging of hepatocellular carcinoma with comparison of tumor size, AFP level, and histologic grade.
    Wolfort RM, Papillion PW, Turnage RH, Lillien DL, Ramaswamy MR, Zibari GB.
    Int Surg; 2010 Apr; 95(1):67-75. PubMed ID: 20480845
    [Abstract] [Full Text] [Related]

  • 4. 11C-acetate and 18F-fluorodeoxyglucose positron emission tomography/computed tomography dual imaging for the prediction of response and prognosis after transarterial chemoembolization.
    Park S, Kim TS, Kang SH, Kim HB, Park JW, Kim SK.
    Medicine (Baltimore); 2018 Sep; 97(37):e12311. PubMed ID: 30212970
    [Abstract] [Full Text] [Related]

  • 5. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma.
    Trojan J, Schroeder O, Raedle J, Baum RP, Herrmann G, Jacobi V, Zeuzem S.
    Am J Gastroenterol; 1999 Nov; 94(11):3314-9. PubMed ID: 10566736
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Predictive Value of 18F-FDG PET/CT for Vascular Invasion in Patients With Hepatocellular Carcinoma Before Liver Transplantation.
    Lin CY, Liao CW, Chu LY, Yen KY, Jeng LB, Hsu CN, Lin CL, Kao CH.
    Clin Nucl Med; 2017 Apr; 42(4):e183-e187. PubMed ID: 28114226
    [Abstract] [Full Text] [Related]

  • 8. Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT.
    Mulé S, Chalaye J, Legou F, Tenenhaus A, Calderaro J, Galletto Pregliasco A, Laurent A, Kharrat R, Amaddeo G, Regnault H, Tacher V, Kobeiter H, Itti E, Luciani A.
    Eur Radiol; 2020 Oct; 30(10):5348-5357. PubMed ID: 32405753
    [Abstract] [Full Text] [Related]

  • 9. Low glucose metabolism in hepatocellular carcinoma with GPC3 expression.
    Li YC, Yang CS, Zhou WL, Li HS, Han YJ, Wang QS, Wu HB.
    World J Gastroenterol; 2018 Jan 28; 24(4):494-503. PubMed ID: 29398870
    [Abstract] [Full Text] [Related]

  • 10. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma.
    Park JW, Kim JH, Kim SK, Kang KW, Park KW, Choi JI, Lee WJ, Kim CM, Nam BH.
    J Nucl Med; 2008 Dec 28; 49(12):1912-21. PubMed ID: 18997056
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of metabolic characteristics and viability of lipiodolized hepatocellular carcinomas using 18F-FDG PET/CT.
    Kim HO, Kim JS, Shin YM, Ryu JS, Lee YS, Lee SG.
    J Nucl Med; 2010 Dec 28; 51(12):1849-56. PubMed ID: 21098794
    [Abstract] [Full Text] [Related]

  • 12. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma.
    Ho CL, Chen S, Yeung DW, Cheng TK.
    J Nucl Med; 2007 Jun 28; 48(6):902-9. PubMed ID: 17504862
    [Abstract] [Full Text] [Related]

  • 13. Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment.
    Yamashige D, Kawamura Y, Kobayashi M, Shindoh J, Kobayashi Y, Okubo S, Muraishi N, Kajiwara A, Iritani S, Fujiyama S, Hosaka T, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ikeda K, Arase Y, Hashimoto M, Kumada H.
    Oncology; 2021 Jun 28; 99(3):169-176. PubMed ID: 33207358
    [Abstract] [Full Text] [Related]

  • 14. The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma.
    Wudel LJ, Delbeke D, Morris D, Rice M, Washington MK, Shyr Y, Pinson CW, Chapman WC.
    Am Surg; 2003 Feb 28; 69(2):117-24; discussion 124-6. PubMed ID: 12641351
    [Abstract] [Full Text] [Related]

  • 15. Early diagnosis of recurrent hepatocellular carcinoma with 18F-FDG PET after radiofrequency ablation therapy.
    Paudyal B, Oriuchi N, Paudyal P, Tsushima Y, Iida Y, Higuchi T, Hanaoka H, Miyakubo M, Takano A, Ishikita T, Endo K.
    Oncol Rep; 2007 Dec 28; 18(6):1469-73. PubMed ID: 17982632
    [Abstract] [Full Text] [Related]

  • 16. Emerging role of 18F-fluorodeoxyglucose positron emission tomography for guiding management of hepatocellular carcinoma.
    Lee SM, Kim HS, Lee S, Lee JW.
    World J Gastroenterol; 2019 Mar 21; 25(11):1289-1306. PubMed ID: 30918424
    [Abstract] [Full Text] [Related]

  • 17. Analysis of gene expression profiles of hepatocellular carcinomas with regard to 18F-fluorodeoxyglucose uptake pattern on positron emission tomography.
    Lee JD, Yun M, Lee JM, Choi Y, Choi YH, Kim JS, Kim SJ, Kim KS, Yang WI, Park YN, Han KH, Lee WJ, Yoo N, Lim SM, Park JH.
    Eur J Nucl Med Mol Imaging; 2004 Dec 21; 31(12):1621-30. PubMed ID: 15278306
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. HRD1 attenuates the high uptake of [18F]FDG in hepatocellular carcinoma PET imaging.
    Li AM, Lin XW, Shen JT, Li M, Zheng QH, Zhou ZY, Shi M.
    Nucl Med Biol; 2021 Dec 21; 96-97():27-34. PubMed ID: 33725499
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.